Losartan dosing for heart failure
Links shared publicly online about this topic.
- 1,596total visits
Losartan dosing for heart failure
View full resource at theheart.org
Tags: Heart, Heart Disease, Heart Failure, High Blood Pressure Medication, Cozaar, Hyzaar
Most Recently Shared on November 17, 2009 at 1:21 pm By:
HEAAL: High-dose trumps low-dose ARB for heart failure in the ACE-inhibitor intolerant http://bit.ly/yt67D #SS09 #aha09
Therapeutic Dosing of Synthetic Antimi Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure - Drugs.com MedNews
drugs.com — “Research by miRagen Therapeutics published in Circulation Sep 6, 2011 - miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on imp” View full resource at drugs.com
Most Recently Shared on September 6, 2011 at 9:16 pm By:
Drugs and Devices OW OW Health
Therapeutic Dosing of Synthetic Antimi Further Demonstrates the Potential of microRNA-208 Inhibition in Tr... http://t.co/MhL9OFA #drug
Family Medicine Article | Heart Failure
mdlinx.com — “The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial” View full resource at mdlinx.com
Most Recently Shared on August 25, 2011 at 6:17 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic he... http://t.co/HQihdkR #FamPractice
Hormone reduces risk of heart failure from chemotherapy, study suggests
sciencedaily.com — “A new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at sciencedaily.com
Most Recently Shared on August 4, 2011 at 10:03 pm By:
Endocrinology Wisdom OW Health
Hormone reduces risk of heart failure from chemotherapy, study suggests: A new study utilizing a heart failure m... http://bit.ly/n6SbkZ
Hormone reduces risk of heart failure from chemotherapy
eurekalert.org — “Now, a new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research, published by Cell Press in the August 2011 issue of the journal Cell Stem Cell, finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at eurekalert.org
Most Recently Shared on August 4, 2011 at 10:03 pm By:
Endocrinology Wisdom OW Health
Hormone reduces risk of heart failure from chemotherapy: ( Cell Press ) Now, a new study utilizing a heart failu... http://bit.ly/r38v8o
Hormone reduces risk of heart failure from chemotherapy, study suggests
sciencedaily.com — “A new study utilizing a heart failure model is providing insight into one way to coax the cardiac stem cells into repairing the damaged heart. The research finds that low doses of erythropoietin (EPO), a hormone best known for controlling the production of red blood cells, might reduce the risk of heart failure associated with some anticancer therapies.” View full resource at sciencedaily.com
Most Recently Shared on August 4, 2011 at 6:16 pm By:
ScienceDaily: Hormone reduces risk of heart failure from chemotherapy, study suggests http://bit.ly/pIFPRi Full http://bit.ly/omumDW
Heart Failure in African Americans: Do We Need Fixed Dose ISDN/HYD?
secure.quantiamd.com — “Join Keith C. Ferdinand, MD, FACC, FAHA, and Chief Science Officer of the Association of Black Cardiologists, as he discusses options for treatment of heart failure in the adult African American population.” View full resource at secure.quantiamd.com
Most Recently Shared on August 4, 2011 at 1:55 pm By:
QuantiaMD Support and Health Social Media
Heart Failure in African Americans: Do We Need Fixed Dose ISDN/HYD? http://ow.ly/5U7yd #MDCHAT
Discussion Board » General Nephrology » Chronic Kidney Disease » CHF and the Use of Lasix in the Setting of CKD4 : Nephrology On-Demand
blog.ecu.edu — “Discussion Board » General Nephrology » Chronic Kidney Disease » CHF and the Use of Lasix in the Setting of CKD4 : Nephrology On-Demand” View full resource at blog.ecu.edu
Most Recently Shared on July 19, 2011 at 9:35 am By:
Nephrology On-Demand Medical Journal and Nephrology
Join the discussion: CHF & the use of high-dose diuretics v. ultrafiltration http://bit.ly/rje4Af #Mdchat, #Clinicaltopics, #kidney, #CHF
LOPRESSOR INJECTION (Metoprolol) drug information from MPR
empr.com — “LOPRESSOR INJECTION (Metoprolol) drug information for CHF and arrhythmias from MPR including side effects, drug interactions, dosing, contraindications and warnings/precautions.” View full resource at empr.com
Most Recently Shared on July 14, 2011 at 4:18 am By:
MPR News: LOPRESSOR INJECTION: Monograph added. http://bit.ly/pS6oAV
Heart Failure Patients Don't Need Continuous Infusion of Diuretics: Study - Yahoo! News
news.yahoo.com — “Read 'Heart Failure Patients Don't Need Continuous Infusion of Diuretics: Study' on Yahoo! News. WEDNESDAY, March 2 (HealthDay News) -- Answering lingering questions about the treatment of acute heart failure, investigators have determined that there are no real differences in how patients fare when they're given diuretic therapy one dose at a time or continuously.” View full resource at news.yahoo.com
Most Recently Shared on July 11, 2011 at 11:57 pm By:
Heart Failure Patients Don't Need Continuous Infusion of Diuretics: Study: WEDNESDAY, March 2 (HealthDay News) ... http://yhoo.it/n5k2Kk
Mount Sinai gene therapy improves cardiac function in people with severe heart failure
news-medical.net — “Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.” View full resource at news-medical.net
Most Recently Shared on June 29, 2011 at 11:58 am By:
Mount Sinai gene therapy improves cardiac function in people with severe heart failure: Researchers at Mount Sin... http://bit.ly/mFPi4d
New gene therapy for heart failure developed
sciencedaily.com — “Researchers have found in a Phase II trial that a new gene therapy stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.” View full resource at sciencedaily.com
Most Recently Shared on June 28, 2011 at 9:29 pm By:
New gene therapy for heart failure developed: Researchers have found in a Phase II trial that a new gene t... http://tinyurl.com/3f67wmc
New gene therapy for heart failure developed
sciencedaily.com — “Researchers have found in a Phase II trial that a new gene therapy stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.” View full resource at sciencedaily.com
Most Recently Shared on June 28, 2011 at 9:10 pm By:
ScienceDaily: New gene therapy for heart failure developed http://bit.ly/j90VBz Full http://bit.ly/jLwt5R
Researchers develop new gene therapy for heart failure
medicalxpress.com — “Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit ...” View full resource at medicalxpress.com
Most Recently Shared on June 28, 2011 at 8:27 pm By:
PhysOrg Health News Health News
Researchers develop new gene therapy for heart failure http://tw.medicalxpress.com/228497233
Nile Therapeutics Announces Dosing Of First Patient In Phase I Study Of Cenderitide
medicalnewstoday.com — “Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, announced dosing of the first patient in a Phase I clinical trial i” View full resource at medicalnewstoday.com
Most Recently Shared on May 4, 2011 at 7:05 am By:
Nile Therapeutics Announces Dosing Of First Patient In Phase I Study Of Cenderitide http://mnt.to/3VmR #heart #heartdisease
What is congestive heart failure? - Daily Dose - Boston.com
boston.com — “Hollywood icon and actress Elizabeth Taylor died today in Los Angeles. She was 79 and had congestive heart failure. Just what does that mean? According...” View full resource at boston.com
Most Recently Shared on March 23, 2011 at 4:04 pm By:
Tammi Jacobs Health Professional
What is congestive heart failure? http://bit.ly/hI0GTz
Advertisement
